Avidity Partners Management LP

Add to watchlist

$4.51 Billion is the total value of Avidity Partners Management LP's 105 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 60.8% .

All

			Value		Shares		↓ Weighting
VRTX	Sell	VERTEX PHARMACEUTICALS INC	$168,040,000	-12.3%	926,400	-2.5%	3.72%	-28.1%
SGEN	Sell	SEAGEN INC	$91,183,000	-9.8%	537,000	-16.1%	2.02%	-26.0%
LLY	Sell	LILLY ELI & CO	$76,247,000	-41.3%	330,000	-41.6%	1.69%	-51.9%
HOLX	Sell	HOLOGIC INC	$69,780,000	-13.5%	945,400	-21.8%	1.55%	-29.1%
CTLT	Sell	CATALENT INC	$52,962,000	-9.3%	398,000	-26.3%	1.17%	-25.7%
EXAS	Sell	EXACT SCIENCES CORP	$35,221,000	-52.0%	369,000	-37.5%	0.78%	-60.6%
NTLA	Sell	INTELLIA THERAPEUTICS INC	$33,672,000	-45.3%	251,000	-33.9%	0.75%	-55.1%
IMAB	Sell	I MABsponsored ads	$32,910,000	-46.2%	454,000	-37.7%	0.73%	-55.9%
CYT	Sell	CYTEIR THERAPEUTICS INC	$29,544,000	-23.7%	1,683,441	-6.9%	0.66%	-37.4%
EPIX	Sell	ESSA PHARMA INC	$19,600,000	-75.1%	2,450,000	-10.9%	0.43%	-79.6%
IPSC	Sell	CENTURY THERAPEUTICS INC	$18,600,000	-36.8%	739,269	-26.3%	0.41%	-48.2%
SANA	Sell	SANA BIOTECHNOLOGY INC	$17,445,000	+14.0%	774,644	-0.5%	0.39%	-6.5%
LFST	Sell	LIFESTANCE HEALTH GROUP INC	$14,500,000	-52.7%	1,000,000	-9.1%	0.32%	-61.2%
HOWL	Sell	WEREWOLF THERAPEUTICS INC	$10,727,000	-5.4%	625,120	-3.9%	0.24%	-22.5%
HARP	Sell	HARPOON THERAPEUTICS INC	$9,406,000	-54.8%	1,190,600	-20.6%	0.21%	-63.0%
ACAD	Sell	ACADIA PHARMACEUTICALS INC	$9,136,000	-60.2%	550,000	-41.5%	0.20%	-67.4%
XLRN	Sell	ACCELERON PHARMA INC	$6,024,000	-86.6%	35,000	-90.2%	0.13%	-89.1%
ZLAB	Sell	ZAI LAB LTDadr	$3,752,000	-78.8%	35,600	-64.4%	0.08%	-82.6%
NAUT	Sell	NAUTILUS BIOTECHNOLOGY INC	$3,684,000	-67.6%	600,000	-46.7%	0.08%	-73.3%
ATAI	Sell	ATAI LIFE SCIENCES NV	$3,235,000	-50.2%	218,730	-37.7%	0.07%	-58.9%
NPCE	Exit	NEUROPACE INC	$0	–	-40,000	-100.0%	-0.03%	–
OMIC	Exit	SINGULAR GENOMICS SYSTEMS IN	$0	–	-50,000	-100.0%	-0.04%	–
CLVS	Exit	CLOVIS ONCOLOGY INC	$0	–	-271,726	-100.0%	-0.04%	–
FLYW	Exit	FLYWIRE CORPORATION	$0	–	-50,000	-100.0%	-0.05%	–
TKNO	Exit	ALPHA TEKNOVA INC	$0	–	-100,000	-100.0%	-0.06%	–
BCTG	Exit	BCTG ACQUISITION CORP	$0	–	-300,000	-100.0%	-0.09%	–
WKME	Exit	WALKME LTD	$0	–	-150,000	-100.0%	-0.12%	–
CMIIU	Exit	CM LIFE SCIENCES II INCunit 02/25/2028	$0	–	-330,000	-100.0%	-0.12%	–
CFLT	Exit	CONFLUENT INC	$0	–	-100,000	-100.0%	-0.13%	–
CELC	Exit	CELCUITY INC	$0	–	-200,000	-100.0%	-0.13%	–
FIGS	Exit	FIGS INCcl a	$0	–	-100,000	-100.0%	-0.14%	–
DNLI	Exit	DENALI THERAPEUTICS INC	$0	–	-86,100	-100.0%	-0.18%	–
CMLF	Exit	CM LIFE SCIENCES INC	$0	–	-525,000	-100.0%	-0.20%	–
PHVS	Exit	PHARVARIS N V	$0	–	-400,000	-100.0%	-0.20%	–
ESPR	Exit	ESPERION THERAPEUTICS INC NE	$0	–	-400,000	-100.0%	-0.23%	–
DOCS	Exit	DOXIMITY INCcl a	$0	–	-150,000	-100.0%	-0.24%	–
MNDY	Exit	MONDAY COM LTD	$0	–	-40,000	-100.0%	-0.24%	–
CRDF	Exit	CARDIFF ONCOLOGY INC	$0	–	-1,395,000	-100.0%	-0.25%	–
PRTA	Exit	PROTHENA CORP PLC	$0	–	-182,000	-100.0%	-0.25%	–
SYNH	Exit	SYNEOS HEALTH INCcl a	$0	–	-175,000	-100.0%	-0.42%	–
ALDX	Exit	ALDEYRA THERAPEUTICS INC	$0	–	-1,450,000	-100.0%	-0.44%	–
DVAX	Exit	DYNAVAX TECHNOLOGIES CORP	$0	–	-3,400,000	-100.0%	-0.90%	–
KDMN	Exit	KADMON HLDGS INC	$0	–	-9,294,600	-100.0%	-0.97%	–
CAH	Exit	CARDINAL HEALTH INC	$0	–	-654,200	-100.0%	-1.01%	–
	Exit	TRILLIUM THERAPEUTICS INC	$0	–	-4,105,000	-100.0%	-1.08%	–
BBIO	Exit	BRIDGEBIO PHARMA INC	$0	–	-673,400	-100.0%	-1.11%	–
CNC	Exit	CENTENE CORP DEL	$0	–	-751,200	-100.0%	-1.48%	–
NEO	Exit	NEOGENOMICS INC	$0	–	-1,367,000	-100.0%	-1.67%	–
BIIB	Exit	BIOGEN INC	$0	–	-183,900	-100.0%	-1.72%	–
MDT	Exit	MEDTRONIC PLC	$0	–	-535,000	-100.0%	-1.80%	–
MRVI	Exit	MARAVAI LIFESCIENCES HLDGS I	$0	–	-2,963,545	-100.0%	-3.34%	–

Original filings

The following EDGAR filing(s) were analyzed to create this report:

View 13F-HR filed 2021-11-15

Signatures

The EDGAR filing(s) were signed by:

Jared Gandy — Chief Financial Officer/Chief Compliance Officer

Top long-term holdings

Name	Quarters owned	Latest quarter owned	Max weighting
NEUROCRINE BIOSCIENCES INC	15	Q3 2023	4.6%
ARVINAS INC	14	Q3 2023	4.9%
ZENTALIS PHARMACEUTICALS INC	14	Q3 2023	4.8%
SYNDAX PHARMACEUTICALS INC	14	Q3 2023	3.2%
IDEAYA BIOSCIENCES INC	13	Q3 2023	2.5%
NATERA INC	13	Q3 2023	1.9%
ALPINE IMMUNE SCIENCES INC	13	Q3 2023	0.5%
ABBVIE INC	12	Q2 2023	9.7%
HORIZON THERAPEUTICS PUB LTD	12	Q3 2022	3.4%
AVANTOR INC	11	Q1 2023	6.0%

View Avidity Partners Management LP's complete holdings history.

Latest significant ownerships (13-D/G)

Avidity Partners Management LP Q3 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
	Filed	Shares	Percentage
Adicet Bio, Inc.^{Sold out}	February 14, 2023	0	0.0%
ALPINE IMMUNE SCIENCES, INC.	February 14, 2023	1,888,887	4.0%
ESSA Pharma Inc.	February 14, 2023	1,855,400	4.2%
Gritstone bio, Inc.	February 14, 2023	2,859,971	3.3%
IVERIC bio, Inc.	February 14, 2023	838,407	0.6%
ONCOSEC MEDICAL Inc^{Sold out}	February 14, 2023	0	0.0%
PhaseBio Pharmaceuticals Inc	February 14, 2023	2,040,000	4.1%
Phathom Pharmaceuticals, Inc.	February 14, 2023	1,900,000	4.6%
Viridian Therapeutics, Inc.^{Sold out}	February 14, 2023	0	0.0%
Anika Therapeutics, Inc.^{Sold out}	February 14, 2022	0	0.0%

View Avidity Partners Management LP's complete significant-ownership history.

Latest filings

Type	Filed
SC 13G	2024-04-09
SC 13G	2024-03-27
13F-HR	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-13
SC 13G/A	2024-02-13
SC 13G/A	2024-02-13

View Avidity Partners Management LP's complete filings history.

All filings

View complete filings history.

Compare quarters

Export Avidity Partners Management LP's holdings